2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Huppert L, Wolf D, Yau C, Brown-Swigart L, Hirst G, Isaacs C, Pusztai L, Pohlmann P, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Veer L, Esserman L, Rugo H. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Annals Of Oncology 2024 PMID: 39477071, DOI: 10.1016/j.annonc.2024.10.018.Peer-Reviewed Original ResearchDistant recurrence-free survivalEarly-stage breast cancerPathological complete responsePathologic complete response rateClinical/molecular featuresComplete responseER-positiveBreast cancerRate of pathological complete responseResponse to neoadjuvant chemotherapyRecurrence-free survivalI-SPY2 trialOptimal treatment selectionNeoadjuvant armER/PR statusLobular histologyNeoadjuvant chemotherapyIII diseaseImmune signaturesNegative diseaseOptimal therapyI-SPY2Excellent outcomesTreatment armsFollow-up
2012
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal Of Clinical Oncology 2012, 30: 729-734. PMID: 22291085, DOI: 10.1200/jco.2011.36.2574.Peer-Reviewed Original ResearchConceptsER-positive patientsIHC-positive patientsER-positive cancersESR1 mRNA expressionGene signature scoreER statusBreast cancerSignature scoreEstrogen receptor-positive cancersMRNA expressionAdjuvant endocrine therapyEndocrine-sensitive tumorsER-negative cohortER-positive cohortER-negative groupER-positive tumorsOverall survival ratePrimary breast cancerER-negative cancersReceptor-positive cancersSafe clinical approachEstrogen receptor mRNAEndocrine therapyER-positiveAffymetrix U133A gene chips
2011
P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry.
Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, Ueno N, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi G, Hatzis C, Symmans W, Pusztai L. P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry. Cancer Research 2011, 71: p1-07-09-p1-07-09. DOI: 10.1158/0008-5472.sabcs11-p1-07-09.Peer-Reviewed Original ResearchER-positive casesER-positive cancersESR1 mRNA expressionGene signature scoreIHC-positive casesLuminal ABreast cancerSignature scoreMRNA expressionER-negative cancersPrimary breast cancerESR1 mRNA levelsEstrogen receptor mRNAER expressionER statusER-positivePositive cancersAffymetrix U133A gene chipsLuminal BSensitive tumorsEstrogen receptorB. ConclusionReceptor mRNAESR1 expressionPositive casesP4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers.
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, Hortobagyi G, Pusztai L, Symmans F, Ueno N. P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers. Cancer Research 2011, 71: p4-16-02-p4-16-02. DOI: 10.1158/0008-5472.sabcs11-p4-16-02.Peer-Reviewed Original ResearchER-negative breast cancerER-positive breast cancerMetastasis-specific genesBone metastasesER statusBreast cancerPrimary invasive breast cancer patientsInvasive breast cancer patientsCox proportional hazards modelER-negative breast cancer cell linesNon-bone metastasisFirst metastatic siteBreast cancer patientsProportional hazards modelBreast cancer cell linesSignificant differencesBiological differencesCancer cell linesMetastatic sitesER-positiveCancer patientsDifferent biological potentialsHazards modelPatientsMetastasisDistinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research 2011, 17: 2591-2601. PMID: 21248301, DOI: 10.1158/1078-0432.ccr-10-1045.Peer-Reviewed Original ResearchConceptsER- cancersPredictive valueBreast cancerP53 signatureWorse distant metastasis-free survivalDistant metastasis-free survivalER-negative breast cancerAdjuvant tamoxifen therapyDifferent molecular subsetsMetastasis-free survivalDifferent prognostic valueNegative breast cancerHigher chemotherapy sensitivityTamoxifen therapyFree survivalBetter prognosisER-positivePoor prognosisPrognostic valuePrognostic markerMolecular subsetsChemotherapy sensitivityMutation statusP53 mutationsMultivariate analysis